AllSight
Companies · CLYM · Pharmaceutical Preparations

Climb Bio, Inc. (CLYM)

Climb Bio, Inc. (CLYM) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Climb Bio, Inc. (CLYM) stock — financials & valuation

Key numbers for Climb Bio, Inc. (CLYM): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 50/100 — a percentile rank of Climb Bio, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$658.8M
EV / EBITDA-9.5×
Return on equity-24.1%
ROIC-33.1%
Debt / equity0.0×
Dividend yield0.0%

Independent of the events above — derived from Climb Bio, Inc.’s own financial statements and shown as context, never as advice.

Sep 3, 2026Above the bar
Climb Bio's CLYM116 clears the PK/PD bar, but IgAN efficacy remains untested
Aug 14, 2026In line
CLYM116 hits Phase 2 on schedule—but brings no patient data
Aug 6, 2026
Quarterly loss beat estimates, but pipeline progress largely met expectations
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact